- Location Information
5522 Sepulveda Blvd
Sherman Oaks, CA 91411
City of Hope is one of the largest oncology groups in Southern California, enabling the delivery of high-quality care to more people in their own communities.
City of Hope is committed to leading-edge, community-based care. Every patient who receives radiation oncology services at City of Hope – whether on the main campus or within the clinical care network – has the right to expect:
Excellence in compassionate, patient-centric care
Short wait times and appointments that are usually scheduled within 72 hours
World-class physicians, nurses and staff performing the latest therapies and technologies
A well-designed facility that optimizes treatment
Consistency of care whether in Duarte or in our other nine radiation-oncology facilities
A robust team of radiation oncology nurses who help navigate the treatment journey
Access to genetic counseling
Integrated wellness services (e.g., nutrition counseling)
City of Hope provides radiation oncology services at practice sites in Glendale, Mission Hills, Riverside, San Bernardino, Santa Clarita, Sherman Oaks, Temecula, West Hills and Wildomar, in addition to its sites in Duarte, Antelope Valley, Arcadia, Corona and South Pasadena.
As at all City of Hope facilities, the rad-onc sites will offer an integrated, interdisciplinary array of services and programs to address the many physical and emotional issues that can arise during and after radiation treatment. In addition, support staff will be available to help patients navigate City of Hope and get access to the resources they need.
Leadership in oncology
Designated as one of only 49 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation, diabetes and numerous breakthrough cancer drugs based on technology developed at the institution.